Emergent BioSolutions Inc. (EBS)
- Previous Close
1.8600 - Open
1.8400 - Bid --
- Ask --
- Day's Range
1.8400 - 2.0600 - 52 Week Range
1.4200 - 10.8800 - Volume
921,407 - Avg. Volume
3,026,188 - Market Cap (intraday)
106.877M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-14.8500 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
www.emergentbiosolutions.com1,600
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EBS
Performance Overview: EBS
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EBS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EBS
Valuation Measures
Market Cap
97.45M
Enterprise Value
845.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.09
Price/Book (mrq)
0.15
Enterprise Value/Revenue
0.83
Enterprise Value/EBITDA
-1.63
Financial Highlights
Profitability and Income Statement
Profit Margin
-72.48%
Return on Assets (ttm)
-4.80%
Return on Equity (ttm)
-74.67%
Revenue (ttm)
1.05B
Net Income Avi to Common (ttm)
-760.5M
Diluted EPS (ttm)
-14.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
111.7M
Total Debt/Equity (mrq)
135.15%
Levered Free Cash Flow (ttm)
-103.41M
Research Analysis: EBS
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: EBS
EBS: What does Argus have to say about EBS?
EMERGENT BIOSOLUTIONS INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice TargetEBS: Lowering target price to $4.00
EMERGENT BIOSOLUTIONS INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice TargetEBS: Lowering target price to $5.00
EMERGENT BIOSOLUTIONS INC has an Investment Rating of SELL; a target price of $5.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice TargetEBS: What does Argus have to say about EBS?
EMERGENT BIOSOLUTIONS INC has an Investment Rating of SELL; a target price of $6.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice Target